Randomized trial · people
Survodutide: up to 13.0% weight loss at 76 weeks in SYNCHRONIZE-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large 76-week phase 3 trial, weekly survodutide led to more weight loss than placebo in people with obesity but no diabetes, and digestive side effects were common.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 725
- Published
- 2026
- Journal
- N Engl J Med
What they tested
The team tested whether once-weekly survodutide leads to more weight loss than placebo in adults with obesity who do not have diabetes.
How the study was done
A phase 3, double-blind, randomized, placebo-controlled trial in 725 adults whose BMI was at least 30, or at least 27 along with a weight-related health problem other than diabetes. For 76 weeks, each person got a weekly shot under the skin of survodutide, raised step by step to 3.6 mg or 6.0 mg, or placebo (a dummy shot), plus lifestyle counseling for everyone.

Model. Individual results vary.
What they found
At week 76, average body weight changed by -12.2% in the 3.6 mg arm, -13.0% in the 6.0 mg arm and -5.4% in the placebo arm. The share of people who lost at least 5% of their weight was 72.6%, 71.9% and 46.3%, respectively, and both survodutide arms beat placebo (P<0.001). Digestive complaints led the list of side effects, and most cases were mild or moderate: 80.9% of the 3.6 mg arm, 89.7% of the 6.0 mg arm and 47.9% of the placebo arm had them. No one died.
What it doesn’t show
People with diabetes were left out, so this trial does not show how survodutide works for them. The study was funded by Boehringer Ingelheim.
The paper
le Roux et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026.
The compound
More studies on Survodutide
- Survodutide: 12.2% weight loss and less liver fat at 48 weeksRandomized trial · people · 2026
- Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trialRandomized trial · people · 2024
- Survodutide: more weight loss than semaglutide in miceAnimal study · mice · 2022
- Every study on Survodutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.